On January 07, 2021, NHS England published an update of the Specialized Services Policy Pipeline (covering the period October 19, 2020 - December 08, 2020). Two new Clinical Commissioning Policies were added to the work program, and six new policies related to radiotherapy, neurosurgery, pulmonology, and in-vitro diagnostics were published.

Dec 2020

Resolution on the agreement of the Spanish Commission of Benefits, Insurance, and Financing regarding proton therapy

In November 2020, the General Directorate of Basic Package of National Health System and Pharmacy Services published the Resolution on the agreement of the Commission of Benefits, Insurance, And Financing in relation to the proton therapy technique. The key points of the agreement include the recommendation for the creation of an interdisciplinary committee in each autonomous community to evaluate each specific case of proton therapy and therapeutic indications.

Jul 2020

Update on the indications for proton and carbon ion therapy by Austrian HTA Institute

On June 16, 2020, HTA Austria – Austrian Institute for Health Technology Assessment (AIHTA), issued an updated report on the indications for proton and carbon ion therapy with an overview of confirmed indications, indications that are only recommended under clinical research, and excluded indications.

May 2019

The Belgian Health Care Knowledge (KCE) released a report of HTA for proton beam therapy in adults

In January 2019, the Belgian Health Care Knowledge (KCE) published a report of health technology assessment that was dedicated to the evaluation of proton beam therapy in adults.

Oct 2018

HTA of Cyberknife, proton beam therapy and Nanoknife for prostate cancer in Austria

In mid-August 2018, the Austrian HTA body, the Ludwig-Boltzmann Institute (LBI), has published a health technology assessment in which they have assessed the efficacy and safety of stereotactic radiotherapy (Cyberknife®), proton beam therapy and irreversible electroporation (Nanoknife®) for localized prostate cancer (PCa). It was concluded, there is inadequate and insufficient evidence to show that three evaluated technologies have either a positive impact on survival and quality of life or the ability to prevent or delay prostatectomy.

Aug 2018

Danish Health Authority has published overview of changes of DRG system for 2019

Six new DRGs have been added for 2019, including proton therapy, insertion of functional implants in the urinary tract or male genitals and replacement of processor in cochleart implant.

Jul 2018

An update on cancer treatment using proton therapy in Spain

On 31st of May, 2018, the Catalan agency for quality and health evaluation, AQuAS, has published an update on the efficacy, effectiveness, safety and cost-effectiveness of the proton therapy for the treatment of cancer.

Apr 2018

MTRC has released 8 European reimbursement reports for radiotherapy

Eight reimbursement reports with the total size of 882 pages cover the most common radiotherapy modalities including brachytherapy, 3D conformal radiation therapy, stereotactic radiosurgery, stereotactic body radiation therapy, intensity-modulated radiotherapy (IMRT), volumetric modulated arc therapy (VMAT), image-guided radiotherapy, proton therapy. The analysis covers procedure coding, payment mechanism, reimbursement tariffs and policy restrictions in 12 EU countries including Austria, Belgium, Denmark, England, Finland, France, Germany, Italy, the Netherlands, Norway, Sweden and Switzerland.

Mar 2018

The DRG package for specialist medical care in 2019 is almost completed

The Dutch Healthcare Authority (Nederlandse Zorgautoriteit) has published a draft version of the DBC package for specialist medical care for 2019 (RZ19a).

Feb 2018

The DRG package for specialist medical care in 2019 is almost completed

The Dutch Healthcare Authority (Nederlandse Zorgautoriteit) has published a draft version of the DBC package for specialist medical care for 2019 (RZ19a).

Jan 2018

Three medical procedures covered with evidence development in Switzerland

The Department of Home Affairs (EDI) in Switzerland decided upon the coverage with evidence development (CED) of two types of positron emission tomography as well as stereotactic radiotherapy (photons) of exudative age-related macular degeneration. The status is given to contested medical services for a specific period which is extended until evidence is complete.